The current status of PARP inhibitors in ovarian cancer.
about
Positron emission tomography imaging in diffuse intrinsic pontine glioma.Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.Advances in ovarian cancer therapy.How can molecular abnormalities influence our clinical approach.The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
P2860
Q42345614-0517B209-AAE0-48C2-A8C5-2545CF9F9A26Q45070718-DE9B2036-AC76-4AC5-B663-B7FAF850D08FQ48104995-E3E6FE42-20F3-4BC2-ACAC-42C86743C9E1Q49896005-2CB923B2-87E9-4DC4-AABC-F85AA50C03B2Q50187396-165ED433-B33F-4BAF-A055-8EFA1D782CB7Q52691505-B71A8942-0C27-4748-863A-1A875DB84F2AQ53730678-E70A711B-8F20-41CA-AE80-3ECC2B535ED1
P2860
The current status of PARP inhibitors in ovarian cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The current status of PARP inhibitors in ovarian cancer.
@en
type
label
The current status of PARP inhibitors in ovarian cancer.
@en
prefLabel
The current status of PARP inhibitors in ovarian cancer.
@en
P2093
P356
P1433
P1476
The current status of PARP inhibitors in ovarian cancer.
@en
P2093
Angela George
Jennifer McLachlan
Susana Banerjee
P304
P356
10.5301/TJ.5000558
P577
2016-09-24T00:00:00Z